Axia Women's Health, a United States-based independent women's health group, announced on Wednesday that it has introduced its clinical research division that intends to advance the understanding and treatment of today's most urgent women's health conditions.
The company has partnered with industry leaders in diagnostic testing, medical devices, and pharmaceutical treatments to advance research within important clinical areas, including but not limited to breast cancer, ovarian cancer, fertility, endometriosis, and sexually transmitted infections.
Presently, the clinical research division at Axia Women's Health covers trial sites across its care centres in Ohio, Kentucky, and Pennsylvania, and intends to expand this offering to other care centres in the coming months.
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon
Enable Injections names new chief operating officer
BridgeBio Pharma and Kyowa Kirin partner on infigratinib for skeletal dysplasias in Japan
Redwood Scientific signs agreement with Jeeva Clinical Trials
Tissue Regenix ships first allograft products in the EU post-HPRA approval
Kromek secures GBP1.3m grant for AI-powered radiation sensor project